Yep. And as for "a bit weak as substantiation for an additive effect", I respectfully suggest you stop with the Dunning Kruger-esque interpretations and read on past the pictures @vrs37:
Professor Kristofer Thurecht, University of Queensland, said, “The combination of Veyonda with LuPSMA
exhibited an impressive synergistic therapeutic response, with sustained and almost complete regression
of the tumour and minimally-observed systemic toxicity. This combined response was not observed in any
of the animals treated with monotherapy.”
Yep. And as for "a bit weak as substantiation for an additive...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $11.03K | 105.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 418372 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 102513 | 3 |
View Market Depth
| Last trade - 15.45pm 27/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |